tirzepatide and prednisone Is Mounjaro a Steroid? Understanding for Weight Management Clinical Impact of Tirzepatide on

High-fat and high-sugar foods tend to trigger the worst nausea on GLP-1 medications

The growth of the market may be driven by increasing prevalence of diabetes and obesity, alongside advancements in drug formulations and delivery methods

Generation I Semaglutide GLP-1 only Peak Weight Loss 14.9% STEP 1 trial 68 weeks Receptor Coverage Single GLP-1 FDA Status Approved (Wegovy, 2021) FIRST PUBLISHED Wilding et al., NEJM 2021 Generation II Tirzepatide GLP-1 + GIP Peak Weight Loss 22.5% SURMOUNT-1 trial 72 weeks Receptor Coverage Dual GLP-1, GIP FDA Status Approved (Zepbound, 2023) First Published Jastreboff et al., NEJM 2022 Generation III Retatrutide GLP-1 + GIP + GCGR Peak Weight Loss 24.2% Phase 2 48 weeks (highest dose) Receptor Coverage Triple GLP-1, GIP, GCGR FDA Status Phase 3 (TRIUMPH program) First Published Jastreboff et al., NEJM 2023 -SELECTED LITERATURE Key Retatrutide research and clinical publications

5 , Cd013743 (2022)

Tirzepatide: Even greater, with average weight loss of 15-22% depending on dose